BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 17, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Oct. 30, 2020

Oct. 30, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aligos, Axovant, Bellicum, Biolinerx, Cerevel, Lilly.
Read More
Coronavirus microscopic model

Bio-Europe: Taking stock of the COVID-19 pipeline

Oct. 29, 2020
By Cormac Sheridan
DUBLIN – The global product development pipeline for COVID-19 is now twice as big as for any particular cancer indication, a major disease like Alzheimer’s or any other infectious disease indication.
Read More

Special Access Program gets mixed reviews from Canadian doctors, medical device experts

Oct. 29, 2020
By David Godkin
TORONTO – Whether it’s President Trump obtaining the drug Regeneron or COVID-19 test kits fast tracked in the U.S. and Canada, this has been the year of temporary emergency approvals for drugs and medical devices. What is sometimes overlooked are permanent programs like Canada’s Special Access Program and the U.S.’s Expanded Access Program, designed to provide therapeutics to patients who have exhausted every avenue for a cure or relief from a devastating disease. 
Read More
Syringes, ampoules, pills and money

New rules let health care pricing out of the box, provide free vaccine

Oct. 29, 2020
By Mari Serebrov
If a new federal rule withstands politics and potential court challenges, U.S. health care prices may finally be freed from their historic black box. The Centers for Medicare & Medicaid Services, along with the Departments of Labor and the Treasury, issued the Transparency in Coverage final rule Oct. 29 requiring most private health plans to disclose pricing and cost-sharing information so Americans will know in advance how much they will have to pay for prescription drugs, medical devices and other health care products and services.
Read More

Regulatory actions for Oct. 29, 2020

Oct. 29, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Chf Solutions, Dia Imaging Analysis, Illuminoss Medical, Medtronic.
Read More

Other news to note for Oct. 29, 2020

Oct. 29, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ai Biomed, Ambra Health, Axonics Modulation Technologies, Biocartis Group, Boston Scientific, Breathonix, Daxor, D-Mark Biosciences, Ekso Bionics Holdings, Epic Sciences, Exact Sciences, Inflammatix, Insightec, Lantheus Holdings, Lifedojo, Medtronic, Nanox, Novocure, Ontrak, Predicine, Rb Medical Supply, S2 Genomics, Sengenics, Simplify Medical .
Read More

BioWorld MedTech’s Diagnostics Extra for Oct. 29, 2020

Oct. 29, 2020
By Meg Bryant
Keeping you up to date on recent developments in diagnostics, including: A case for pooled testing of SARS-CoV-2; FIT as effective as colonoscopy in ruling out suspected colorectal cancer; Looking to comparative genomics analysis to explain COVID-19 susceptibility.
Read More

Regulatory actions for Oct. 29, 2020

Oct. 29, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apstem, Asieris, Avrobio, Genprex, Insignis, Mesoblast, Oncosec, Pepromene, Rafael, Regeneron, Tricida.
Read More

Other news to note for Oct. 29, 2020

Oct. 29, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AB2 Bio, Abcellera, Acura, Anabios, Arcus, Astrazeneca, Atyr, Bone Therapeutics, Catalent, Cstone, Dr. Reddy’s, Emulate, Engene, Field Trip, Dr. Reddy’s, Immatics, Immutep, Inivata, Intec, Jaguar, Kodiak, Legochem, Maverick, Mebias, Merck, Moderna, Moleculin, Novocure, Orion, Sanofi, Sorrento, Synedgen, Syneos, Synteract, Takeda.
Read More

In the clinic for Oct. 29, 2020

Oct. 29, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Aerie, Affyimmune, Anheart, Annovis, Avillion, Biolinerx, Chemocentryx, Connect, Frequency, Hookipa, Humanigen, Immunomolecular, Kiniksa, Kintor, Leap, Leo, Lilly, Mallinckrodt, Moderna, Plus, Regeneron.
Read More
Previous 1 2 … 346 347 348 349 350 351 352 353 354 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 16, 2026.
  • AI-generated  illustration of a neuron with tau protein aggregation

    AAIC 2026: Age of amyloid is being joined by time of tau

    BioWorld
    The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Illustration of T cells attacking cancer

    GABA signaling linked to immune resistance in some tumors

    BioWorld
    Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing